A strategy to inhibit aberrant NF-κB activation in a more specific fashion, and thus potentially reducing systemic toxicity, would be to target the downstream mediators of the pathway, including the individual NF-κB transcription factors or select target genes that are oncogenic in lymphomas. Here, NFKB1 is linked to lymphoma.